News Briefing channel feed – Endpoints News

News Briefing channel feed

Roche will have to wait on its big MS drug application; Pfizer ties up with BioInvent on new antibodies for cancer

9 years ago

Novartis adds opthalmology buyout in year-end deal spree; Tesaro gets a speedy FDA review for niraparib

9 years ago

Sanger spinout gets $10M, tackles the microbiome frontier; Adaptimmune and Bellicum partner T cell tech

9 years ago

Reeling Ophthotech eviscerates staff, laying off up to 135; Booming Regeneron adds more space

9 years ago

Lonza bags Capsugel and its oral drug delivery tech for $5.5B: Biotech vet Truex named COO at Synlogic

9 years ago

Pfizer inks an early-stage collaboration deal as it invests in another startup; Stem cell startup lands cardiac tech

9 years ago

Scott Gottlieb takes a turn in the spotlight for FDA candidates; Triumphant Achaogen lines up stock sale

9 years ago

Maris pulls the plug on biotech fund, goes back on hiatus; Flexion files and Sanofi brings out the ax

9 years ago

Synergy outlines upbeat PhIII data; Bluebird and Blueprint raising $375M

9 years ago

Virtual biotech star Mark de Souza signs up to help lead the team on a new co launch; Takeda partners with RNA biotech Arcturus on NASH

9 years ago

Ariad’s brigatinib scores 15.6 month PFS rate; Neurimmune backs ALS spinout

9 years ago

GSK vet Deborah Waterhouse takes CEO spot at Viiv; Is Sanofi pondering an Actelion bid?

9 years ago

Merck is hiring as it shows off new Bay Area campus plans; Lilly, though, is reportedly laying off sales staff

9 years ago

Retreating Arrowhead axes CSO in RNAi rout; Impel raises $36M for platform tech

9 years ago

Magic mushrooms treat depression, anxiety felt by cancer patients; Merck wins a speedy review schedule for latest Keytruda initiative

9 years ago

Heptares bags GPCR tech in $12M G7 buyout; Pfizer reports PhIII success for Herceptin biosim

9 years ago

Another Humira copycat comes through in PhIII; Tetra Discovery adds $10M for Alzheimer’s drug development

9 years ago

Porges sees the pros — and cons — for Biogen in Lilly’s Alzheimer’s snafu; Idera forges development pact; UK government adds more cash for R&D programs

9 years ago

Pfizer blueprints $200M R&D campus; Galapagos bags $50M milestone from Gilead

9 years ago

Fate raises $57M; Biogen vet named CSO at Scholar Rock

9 years ago

Halozyme shares drop after AbbVie punts a failed program; Celgene buys another cancer drug

9 years ago

Motif strikes a deal needed to trigger Nasdaq IPO; OncoGenex cuts more staffers to conserve cash

9 years ago

Another South San Francisco biotech campus takes shape; WSJ: Feds plan charges in Valeant kickback scheme

9 years ago

Bristol-Myers partners with Enterome on a gut-level approach to immuno-oncology; MorphoSys adds $126M

9 years ago

First page Previous page 73 74 757677 78 79 Next page Last page